慢性阻塞性肺病 (COPD):药物治疗的发展
Dave Singh1,2, Andrew Higham3, Alexander G Mathioudakis3,4
1Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK. dsingh@meu.org.uk.
Drugs
|May 20, 2025
概括
在慢性阻塞性肺病 (COPD) 中,精准医学使用血中乙氨基酸细胞计数 (BEC) 来指导治疗. 患有较高BEC的患者从吸入性皮质类固醇和单克隆抗体等向治疗中获益更多.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 精准医学是一门精准的医学.
背景情况:
- 慢性阻塞性肺病 (COPD) 管理旨在缓解症状,增强运动能力,并减少长期风险,如恶化,肺功能下降和死亡率.
- 一个特定的COPD患者小组表现出2型炎症,可通过血中异氨基细胞计数 (BEC) 的升高来识别.
- 较高的BEC水平与针对2型炎症的治疗方法,如吸入性皮质类固醇和单克隆抗体的更显著的治疗反应相关.
研究的目的:
- 审查COPD药理治疗的最新进展.
- 要突出血中乙酸细胞计数 (BEC) 作为COPD精密医学的生物标志物的作用.
- 讨论吸入组合疗法,恩西芬和单克隆抗体在COPD管理中的最佳使用.
主要方法:
- 审查关于COPD药理干预的当前文献.
- 对调查2型炎症和BEC在COPD中的作用的研究分析.
- 对 COPD 治疗中的吸入性皮质类固醇,恩西芬和单克隆抗体的证据评估.
主要成果:
- 血中乙氨基酸细胞计数 (BEC) 作为一种有价值的生物标志物,用于识别COPD患者从2型炎症向治疗中受益.
- 吸入性皮质类固醇和单克隆抗体在具有较高BEC的特定COPD患者子组中显示出有效性.
- 恩西芬是一种新型的吸入固酶抑制剂,在COPD治疗中显示出潜力.
结论:
- 使用BEC作为生物标志物有助于在COPD药物治疗中采用精准医学方法.
- 优化吸入组合治疗和结合新型药物,如恩西芬和单克隆抗体可以改善COPD的结果.
- 基于炎症概况的个性化药理策略对于有效的COPD管理至关重要.
相关概念视频
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
166
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
166
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
01:20COPD: Pathogenesis and Clinical Features
219
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
219
01:17Drugs Used in Lower Respiratory Disorders: Overview
329
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
329